Ranbaxy Laboratories Limited
USPTO PatentsView assignee record - 8 granted patents across 4 technology areas, recorded in grant years 2015–2015. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07D (Heterocyclic Compounds).
The verdict
According to USPTO PatentsView, Ranbaxy ranks #33,004 of 49,997 tracked US assignees by granted-patent volume, with 8 patents across 4 technology areas.
- #33,004
- of 49,997 US assignees by volume
- 7th percentile
- by Innovation Score (20.4/100)
- 9.6
- avg claims per patent
- -100%
- grant velocity, last 5 yrs
USPTO PatentsView assignee plate
Corpus R33004 · Foreign Corporation #33,004 · 8 grants
GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-PAR · TYPE-FRNCORP · VEL-DROP · BOOK-FULL
- GRANTS-MICRO 8 grants
- MID-PACK #33,004/49,997
- PHOTO-FINISH R-Tech Ueno
- CPC-NARROW C07D · 4 areas
- INNOV-THIN 20.4/100
- CLAIMS-PAR 9.6 claims/avg
- TYPE-FRNCORP Foreign Corp
- VEL-DROP -100% vel
- BOOK-FULL 10/10 fields
Nearest grant-volume peer: R-Tech Ueno, Ltd. (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
How Ranbaxy’s 20.4 Innovation Score adds up
The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.
Innovation-score neighbourhood around Ranbaxy
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
- Qualcomm Incorporated · highest
Qualcomm Incorporated · highest
85 score
- Ranbaxy Laboratories · this assignee 20
Ranbaxy Laboratories · this assignee
20 score
- 3D Lighting… · lowest 7
3D Lighting… · lowest
7 score
What this shows Ranbaxy's Innovation Score is 20.4/100 (7th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Does more volume mean deeper claims for Ranbaxy?
Each dot is one of Ranbaxy’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Ranbaxy’s own 9.6 claims/patent is at or below the 13.4 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.
Where Ranbaxy's grants concentrate
Ranbaxy Laboratories Limited is a focused PatentsView assignee: 4 CPC subclasses with 50% of grants classified under C07D (Heterocyclic Compounds). By volume, Ranbaxy sits between R-Tech Ueno, Ltd. and Rayotek Scientific, Inc..
Who files at Ranbaxy's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- R-tech Ueno
R-Tech Ueno, Ltd.
8 patents
- R Weiss Verpackun…
R. Weiss Verpackungstechnik GmbH & Co. KG
8 patents
- R3 Collaboratives
R3 Collaboratives, Inc.
8 patents
- Raisio Nutrition
Raisio Nutrition Ltd
8 patents
- Raontech
Raontech, Inc.
8 patents
- Raydiall
Raydiall
8 patents
- Raylase
Raylase GmbH
8 patents
- Rayotek Scientific
Rayotek Scientific, Inc.
8 patents
- Ranbaxy Laborator… ◀
Ranbaxy Laboratories Limited
8 patents
What this shows Ranbaxy holds 8 patents at rank #32,981, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Ranbaxy
By rank, the assignees closest to #32,981 in granted patent volume.
- R-Tech Ueno, Ltd. #32,977 · 8 patents
- R. Weiss Verpackungstechnik GmbH & Co. KG #32,978 · 8 patents
- R3 Collaboratives, Inc. #32,979 · 8 patents
- Raisio Nutrition Ltd #32,980 · 8 patents
- Raontech, Inc. #32,982 · 8 patents
- Raydiall #32,983 · 8 patents
- Raylase GmbH #32,984 · 8 patents
- Rayotek Scientific, Inc. #32,985 · 8 patents
Leaders in C07D (Heterocyclic Compounds)
Other assignees with the most granted patents in Ranbaxy's primary technology class.
Ranbaxy's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
20 7th percentile higher than 7% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 8 | 100.0% |
Which technologies does Ranbaxy Laboratories Limited patent most?
Top 4 of 4 technology areas
Data Source
USPTO PatentsView, US granted patents 2015–2025
What to do with this data
Ranbaxy Laboratories Limited's patent record in context - here's where to go next.
- Ranbaxy Laboratories Limited's lead technology class is C07D (Heterocyclic Compounds), 50% of its portfolio - see every assignee active in that class. Explore C07D
- Ranked #33,004 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
- Compare Ranbaxy Laboratories Limited against R-Tech Ueno, Ltd., an assignee filing at a similar volume. Compare portfolios
- Innovation Score of 20.4/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.